Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 12Active not recruiting 9Completed 8Not yet recruiting 3Unknown 1Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 18Other hematologic neoplasm 3Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

venetoclax 37Azacitidine 23fludarabine 19Cytarabine 19Cyclophosphamide 15Specimen Handling 14blinatumomab 13Biopsy 12Busulfan 8Dexamethasone 7Melphalan 6Daunorubicin 6Whole-Body Irradiation 5Vincristine 5Thiotepa 5Methotrexate 5gilteritinib 4daratumumab 4Tacrolimus 4Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Imatinib Mesylate 4Idarubicin 4Decitabine 4Blood Specimen Collection 4zanubrutinib 3selinexor 3ruxolitinib 3revumenib 3olutasidenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × zanubrutinib × Other hematologic neoplasm × Clear all
NCT07321652 2026-01-07

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
466 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07003464 2025-06-04

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

The First Hospital of Jilin University

Phase 2 Not yet recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06367374 2024-04-16

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
66 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡